This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group, event-driven, superiority, group sequential study to evaluate the efficacy and safety of milvexian in participants enrolled within 7 days of an Acute Coronary Syndrome. Participants will receive either milvexian/ placebo on a background of standard-of-care antiplatelet therapy. The total study duration is approximately 3.5 years.
